Table 4.
Percent of trials with specific biomarkers included (this calculation is based on the number of trials in which the inclusion of biomarkers is described)
Biomarker | % of trials |
|
---|---|---|
Phase III | Phase II | |
1. CSF amyloid | 27.7 | 25 |
2. CSF tau | 22.2 | 21.1 |
3. FDG-PET | 19.4 | 11.5 |
4. vMRI | 25 | 15.3 |
5. Plasma amyloid | 8.3 | 5.7 |
6. Plasma tau | 0 | 3.8 |
7. Amyloid PET | 22.2 | 9.6 |
8. Tau PET | 2.7 | 0 |